Zoetis Financial Model
Pharmaceuticals Company Financials Example (Free Excel Download)
Zoetis is the world's largest animal health company, discovering, developing, manufacturing, and commercialising medicines, vaccines, and diagnostic products.
professionals from Deloitte
Used by professionals from
About this model
This model forecasts Zoetis's revenue growth, margin expansion, and cash flow generation to determine its equity valuation and assess the impact of its companion animal product pipeline on long-term earnings.
Zoetis is the world's largest animal health company, discovering, developing, manufacturing, and commercialising medicines, vaccines, and diagnostic products. The company serves veterinarians, livestock producers, and pet owners across more than 100 countries.
Business segments by revenue contribution:
- United States (U.S.): Approximately 54% of total revenue.
- International: Approximately 45% of total revenue.
- Contract Manufacturing & Human Health: Approximately 1% of total revenue.
Within the regional segments, revenue is further split by species into Companion Animal (roughly 68% of total) and Livestock (roughly 31% of total).
The business model is a traditional pharmaceutical model applied to animal health, characterised by high R&D investment, patent-protected product portfolios, and strong pricing power, but with lower generic cliff risks compared to human pharma. Zoetis holds the number one competitive position globally in animal health, competing with Boehringer Ingelheim, Merck Animal Health, and Elanco. A recent major event was the October 2024 divestiture of its medicated feed additive (MFA) product portfolio, which requires adjustments to historical revenue bases to calculate organic growth.
The downloadable Zoetis financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsZoetis financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B |
| Gross profit | $5.47B | $5.63B | $5.98B | $6.54B | $6.80B |
| Cost of sales(a | $2.30B | $2.45B | $2.56B | $2.72B | $2.67B |
| Net income | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Zoetis
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
U.S. Companion Animal
- Segment name: U.S. Companion Animal
- Revenue driver formula: Prior Year Revenue x (1 + Volume Growth + Price Increase)
- Historical growth rate: 4% to 6% historically.
- Key growth levers and headwinds: Driven by the humanisation of pets, increased veterinary visits, and blockbuster monoclonal antibody therapies (Librela, Cytopoint) and parasiticides (Simparica Trio). Headwinds include veterinary clinic staffing shortages and macroeconomic pressures on consumer discretionary spending.
- Pricing dynamics: High pricing power; price increases typically contribute 2% to 4% of annual growth.
- Revenue recognition notes: Recognised upon transfer of control (shipment or delivery) to distributors or veterinary practices.
- Seasonality: Parasiticide sales are typically stronger in the northern hemisphere spring and summer (Q2 and Q3).
U.S. Livestock
- Segment name: U.S. Livestock
- Revenue driver formula: Herd Size x Treatment Penetration x Price per Dose
- Historical growth rate: Flat to declining (recently -14% reported, though heavily impacted by the MFA divestiture).
- Key growth levers and headwinds: Driven by cattle, swine, and poultry production volumes. Headwinds include generic competition, the MFA portfolio divestiture, and weather-related herd liquidations.
- Pricing dynamics: Highly competitive and sensitive to producer economics and commodity meat prices.
- Revenue recognition notes: Standard point-in-time recognition upon delivery.
- Seasonality: Peak sales often align with autumn cattle runs and spring processing.
International Companion Animal
- Segment name: International Companion Animal
- Revenue driver formula: Prior Year Revenue x (1 + Organic Volume Growth + Price Increase) x (1 + FX Impact)
- Historical growth rate: 5% to 7% operational growth.
- Key growth levers and headwinds: Expanding middle class in emerging markets driving pet ownership, and the international rollout of key franchises like Librela and Solensia. Foreign exchange translation is a persistent headwind.
- Pricing dynamics: Varies by region, subject to local economic conditions and competitive dynamics.
- Revenue recognition notes: Standard point-in-time recognition.
- Seasonality: Similar to the U.S. but smoothed slightly by southern hemisphere markets (e.g., Brazil, Australia).
International Livestock
- Segment name: International Livestock
- Revenue driver formula: Prior Year Revenue x (1 + Organic Volume Growth + Price Increase) x (1 + FX Impact)
- Historical growth rate: 2% to 4% operational growth.
- Key growth levers and headwinds: Global population growth driving protein demand. Headwinds include disease outbreaks (e.g., African Swine Fever) and currency depreciation in emerging markets.
- Pricing dynamics: Competitive, heavily influenced by local agricultural economics.
- Revenue recognition notes: Standard point-in-time recognition.
- Seasonality: Varies widely by geography and species.
Contract Manufacturing & Human Health
- Segment name: Contract Manufacturing & Human Health
- Revenue driver formula: Contracted Volume x Toll Manufacturing Fee
- Historical growth rate: Highly variable, generally flat over the long term.
- Key growth levers and headwinds: Opportunistic utilisation of excess manufacturing capacity.
- Pricing dynamics: Contractual tolling rates.
- Revenue recognition notes: Recognised as services are performed or products are delivered.
- Seasonality: None material.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Raw materials, active pharmaceutical ingredients (APIs), manufacturing labour, overhead, freight, and inventory obsolescence charges.
- Gross margin range: 69.5% to 71.7% over the last 5 years (trending upwards).
- Key input costs and commodity exposures: Chemical precursors, biological materials, and energy costs for manufacturing facilities.
- How COGS scales with revenue: Scales linearly with volume, but gross margin percentage expands with price increases and a mix shift towards higher-margin companion animal therapeutics (monoclonal antibodies).
Operating Expenses
- R&D: Typically 6% to 8% of revenue. Covers discovery, clinical trials, and regulatory approval processes for new animal medicines. Zoetis expenses most R&D as incurred.
- SG&A: Typically 24% to 26% of revenue. Driven by a large direct sales force calling on veterinary clinics and livestock producers, plus direct-to-consumer marketing (e.g., TV ads for Apoquel).
- Depreciation & Amortisation: Approximately 4% to 5% of revenue. Heavily weighted towards amortisation of acquired intangible assets.
- Stock-Based Compensation: Approximately 1% to 1.5% of revenue.
- Restructuring / one-time charges: Occasional charges related to manufacturing network optimisation or post-M&A integration.
Margin Profile
- Gross margin: 69.5% to 71.7%.
- EBITDA margin: 40.0% to 43.0%.
- Operating margin: 36.0% to 38.0%.
- Net margin: 26.0% to 28.0%.
- Margin trend: Expanding. The shift away from lower-margin livestock products (like the divested MFA portfolio) towards high-margin companion animal biologics is driving structural margin improvement.
Balance Sheet Structure
- Total assets: Approximately $15.5 billion.
- Key asset categories: Inventory, Accounts Receivable, Property, Plant & Equipment (PP&E), Goodwill, and Identifiable Intangible Assets.
- Goodwill & intangibles: Represent approximately 35% to 40% of total assets, reflecting historical acquisitions (e.g., Abaxis, Jurox).
- Working capital profile:
- Days Sales Outstanding (DSO): 55 to 65 days.
- Days Inventory Outstanding (DIO): 180 to 220 days (high due to complex biological manufacturing lead times).
- Days Payable Outstanding (DPO): 60 to 75 days.
- Net working capital as % of revenue: 15% to 20%.
- Is working capital positive or negative? Positive. The company requires significant inventory to prevent stockouts of critical medicines.
- PP&E: Manufacturing facilities, laboratories, and equipment. Useful lives range from 15 to 40 years for buildings and 3 to 20 years for equipment.
- Right-of-use assets: Material but manageable, typically around $250 to $300 million.
Capital Expenditure & Investment
- Capex as % of revenue: 5% to 7% historically.
- Maintenance capex vs. growth capex: Approximately 40% maintenance, 60% growth (expanding monoclonal antibody manufacturing capacity).
- Major capex programmes underway: Significant investments in expanding biological manufacturing capacity in the U.S. and Ireland to support the Librela and Solensia rollouts.
- Capitalised software: Minimal relative to physical plant investments.
- M&A pattern: Bolt-on acquirer. Zoetis frequently acquires smaller diagnostic firms, genetic testing companies, or regional distributors to expand its ecosystem.
- Typical acquisition multiple paid: 15x to 20x EBITDA for high-growth companion animal assets.
Debt & Capital Structure
- Total debt: Approximately $9.1 billion to $9.2 billion.
- Debt/EBITDA ratio: Approximately 2.0x to 2.5x.
- Credit rating: Investment grade (BBB/Baa1).
- Key debt instruments: Senior unsecured notes (bonds) and a $1.25 billion revolving credit facility. Recently issued $2.0 billion in convertible senior notes due 2029.
- Maturity profile: Well-laddered, with average maturity exceeding 5 years.
- Interest rate profile: Predominantly fixed-rate bonds.
- Covenants: Standard investment-grade covenants (e.g., maximum leverage ratios on the revolver).
- Share repurchase programme: Highly active. The Board approved a $6.0 billion multi-year share repurchase programme in 2024.
- Dividend policy: Payout ratio of roughly 20% to 25% of adjusted net income, with a history of double-digit annual dividend growth.
Cash Flow Characteristics
- Operating cash flow conversion: Strong, typically 1.1x to 1.2x of GAAP Net Income.
- Free cash flow margin: 20% to 25% of revenue.
- Major non-cash items: Depreciation, amortisation of acquired intangibles, and stock-based compensation.
- Working capital cash flow impact: Inventory builds for new product launches can be a material use of cash in specific quarters.
- Capex intensity: Moderate (5% to 7% of revenue), but highly strategic for biologics manufacturing.
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are generally aligned with the adjusted effective tax rate of approximately 21%.
Sheet Structure
- Assumptions: Hardcoded inputs for macroeconomic drivers, segment growth rates, margin profiles, tax rates, and capital return policies.
- Revenue Build: Detailed forecast of revenue split by U.S. Companion Animal, U.S. Livestock, International Companion Animal, International Livestock, and Contract Manufacturing.
- Income Statement: Consolidated P&L from Revenue down to Net Income and EPS, mirroring the 10-K format.
- Balance Sheet: Standard assets, liabilities, and equity. Must include specific lines for Goodwill, Intangible Assets, and Short-Term Borrowings.
- Cash Flow Statement: Indirect method starting from Net Income, adjusting for D&A, working capital changes, capex, debt issuance/repayment, and shareholder returns.
- Working Capital Schedule: Calculation of Accounts Receivable, Inventory, and Accounts Payable based on DSO, DIO, and DPO days.
- Debt & Interest Schedule: Tranche-by-tranche build of senior notes, convertible notes, and revolver, calculating interest expense and tracking maturities.
- PPE & Intangibles Schedule: Capex additions, depreciation waterfall, and amortisation of acquired intangibles.
- DCF Valuation: Unlevered free cash flow calculation, WACC build, terminal value, and implied share price.
Key Financial Relationships
- U.S. Companion Animal Revenue = Prior Year U.S. Companion Animal Revenue * (1 + U.S. Companion Animal Organic Growth Rate)
- International Companion Animal Revenue = Prior Year International Companion Animal Revenue * (1 + International Companion Animal Organic Growth Rate) * (1 + FX Impact)
- Total Revenue = U.S. Companion Animal Revenue + U.S. Livestock Revenue + International Companion Animal Revenue + International Livestock Revenue + Contract Manufacturing Revenue
- Cost of Sales = Total Revenue * (1 - Gross Margin %)
- Gross Profit = Total Revenue - Cost of Sales
- R&D Expense = Total Revenue * R&D % of Revenue
- SG&A Expense = Total Revenue * SG&A % of Revenue
- EBITDA = Gross Profit - R&D Expense - SG&A Expense + Depreciation & Amortisation
- Accounts Receivable = (Total Revenue / 365) * DSO
- Inventory = (Cost of Sales / 365) * DIO
- Accounts Payable = (Cost of Sales / 365) * DPO
- Interest Expense = Average Total Debt Balance * Weighted Average Interest Rate
- Share Count = Prior Year Share Count - (Share Repurchases / Average Share Price)
- Dividends Paid = Share Count * Dividend Per Share
Cross-Sheet Dependencies
- The Assumptions sheet feeds all growth rates and margin targets into the Revenue Build and Income Statement.
- The Revenue Build feeds the top line of the Income Statement.
- Revenue and COGS from the Income Statement feed the Working Capital Schedule to calculate AR, Inventory, and AP balances.
- The Working Capital Schedule feeds the operating assets and liabilities on the Balance Sheet and the changes in working capital on the Cash Flow Statement.
- The PPE & Intangibles Schedule feeds D&A to the Income Statement and Cash Flow Statement, and ending balances to the Balance Sheet.
- The Debt & Interest Schedule creates a circularity: Interest expense reduces Net Income, which reduces Cash Flow, which dictates the need for Revolver borrowing, which in turn changes the Interest expense. This requires a circularity breaker (toggle) in the model.
- The Cash Flow Statement ending cash balance feeds the Balance Sheet cash line.
Sign Convention
- Revenues and Assets: Entered and displayed as positive numbers.
- Expenses (COGS, SG&A, R&D, Interest, Taxes): Entered as positive assumptions (e.g., SG&A is 25% of revenue) but subtracted in P&L formulas (e.g., Gross Profit - SG&A).
- Liabilities and Equity: Entered and displayed as positive numbers on the Balance Sheet.
- Cash Flow Statement: Cash inflows are positive; cash outflows (capex, debt repayment, dividends, share repurchases) are negative.
Things Most Likely to Go Wrong
- The divestiture of the medicated feed additive (MFA) portfolio in late 2024 distorts historical reported growth; the model must use organic operational growth rates to forecast future baseline revenue.
- Foreign currency translation is a massive swing factor for Zoetis (e.g., a $250 million revenue drag projected for 2025). The model must explicitly separate organic growth from FX impacts.
- Zoetis relies heavily on its top 5 products (Simparica, Apoquel, Cytopoint, Librela, ceftiofur), which generate over 40% of total revenue. A generic entry against any of these will break a top-down revenue forecast.
- Inventory days (DIO) are unusually high (around 200 days) compared to standard corporates because of the long lead times required for biological manufacturing. Do not normalise this to standard retail/manufacturing levels.
- Amortisation of acquired intangibles is significant and is excluded from Zoetis's "Adjusted Net Income". The model must calculate both GAAP Net Income and Adjusted Net Income to match management guidance.
- The company recently issued $2.0 billion in convertible notes. The model must account for the potential share dilution if the stock price exceeds the conversion threshold.
- Stock-based compensation runs at approximately 1.5% of revenue. Excluding it from adjusted EBITDA flatters margins; ensure it is added back in the cash flow statement but treated as a real economic cost in valuation.
- The effective tax rate is highly sensitive to the geographic mix of earnings. A flat statutory U.S. rate will overstate tax expense; use the guided adjusted effective tax rate of ~21%.
Validation Checks
- Total Gross Margin should remain in the 70.0% to 72.5% range; flag if it drops below 69% or exceeds 73%.
- EBITDA Margin should be between 40% and 43%; flag if outside this band.
- Capex as a % of revenue should run between 5% and 7%; flag if it drops below 4% (indicating underinvestment in manufacturing).
- Debt/EBITDA should remain below 3.0x to maintain the investment-grade rating.
- Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period.
- OCF/Net Income conversion should be >1.0x; flag if earnings quality deteriorates below 1.0x.
- The sum of the four main revenue segments plus contract manufacturing must exactly equal Consolidated Total Revenue.
- Dividend payout ratio should remain between 20% and 30% of Adjusted Net Income.
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| U.S. Companion Animal Organic Growth | 4.0 | % | Based on 2024/2025 actuals and stabilising clinic traffic |
| U.S. Livestock Organic Growth | 2.0 | % | Normalised growth post-MFA divestiture |
| Int'l Companion Animal Organic Growth | 6.0 | % | Driven by Librela rollout and emerging market pet ownership |
| Int'l Livestock Organic Growth | 4.0 | % | Steady global protein demand |
| Contract Manufacturing Growth | 0.0 | % | Non-core segment, assumed flat |
| FX Impact on Int'l Revenue | -2.0 | % | Near-term headwind based on 2025 management guidance |
| Gross Margin | 71.7 | % | Actual reported LTM gross margin for 2025 |
| R&D as % of Revenue | 7.0 | % | Historical average required to maintain pipeline |
| SG&A as % of Revenue | 24.5 | % | Historical average, reflecting direct sales force model |
| D&A as % of Revenue | 4.5 | % | Based on historical depreciation and intangible amortisation |
| Effective Tax Rate | 21.0 | % | Management guidance for 2025 adjusted effective tax rate |
| Days Sales Outstanding (DSO) | 60 | Days | Calculated from historical AR and revenue |
| Days Inventory Outstanding (DIO) | 200 | Days | Calculated from historical inventory and COGS |
| Days Payable Outstanding (DPO) | 65 | Days | Calculated from historical AP and COGS |
| Capex as % of Revenue | 6.0 | % | Midpoint of historical 5-7% range |
| Average Interest Rate on Debt | 4.5 | % | Weighted average cost of existing fixed and floating debt |
| Share Repurchases | 1500 | $ Millions | Run-rate based on recent $6B authorisation |
| Dividend Payout Ratio | 25.0 | % | Aligned with historical capital return policy |
| WACC | 7.5 | % | Standard discount rate for large-cap defensive pharma |
| Terminal Growth Rate | 2.5 | % | Long-term inflation plus slight premium for animal health tailwinds |
Data Sources & Benchmarks
- Filings: SEC EDGAR database (10-K, 10-Q, 8-K) and the Zoetis Investor Relations website.
- Key Peers: Elanco Animal Health (ELAN), IDEXX Laboratories (IDXX), Phibro Animal Health (PAHC), Merck (MRK - Animal Health division).
- Industry Data: American Veterinary Medical Association (AVMA) for clinic traffic data, USDA for livestock herd sizes and meat pricing.
- Consensus Estimates: FactSet or Bloomberg for forward-looking street estimates on revenue and adjusted EPS.
- Proprietary Data: Credit card panel data for U.S. veterinary clinic spending trends.
Sources
- Zoetis Q4 and Full Year 2024 Results Press Release (https://investor.zoetis.com)
- Zoetis Q4 and Full Year 2025 Results Press Release (https://investor.zoetis.com)
- Zoetis 2024 Annual Report on Form 10-K (https://www.sec.gov)
- Macrotrends Zoetis Debt and Margin Data (https://www.macrotrends.net/stocks/charts/ZTS/zoetis/long-term-debt)
- Investing.com Zoetis Gross Profit Margin (https://www.investing.com)
Do more with the Zoetis model
Frequently asked
What does Zoetis do as an animal health company?+
Zoetis is the world's largest animal health company, focused on discovering, developing, manufacturing, and commercializing medicines, vaccines, and diagnostic products. It serves veterinarians, livestock producers, and pet owners across over 100 countries with a business model similar to human pharmaceuticals.
What are the primary revenue drivers for Zoetis?+
Zoetis generates revenue primarily from its United States and International segments, with the U.S. contributing approximately 54% of total revenue. Within these regions, Companion Animal products account for roughly 68% of total revenue, while Livestock products contribute about 31%.
What is the assumed revenue growth rate in the Zoetis financial model?+
The financial model for Zoetis assumes a revenue growth rate of approximately 8.1% for its forecast horizon. This growth, along with margin expansion and cash flow generation, is used to determine the company's equity valuation.
What is the main purpose of the Zoetis financial model?+
The primary purpose of the Zoetis financial model is to forecast the company's revenue growth, margin expansion, and cash flow generation. This analysis is crucial for determining its equity valuation and assessing the long-term earnings impact of its companion animal product pipeline.
Can I download an Excel financial model for Zoetis?+
Yes, an Excel financial model for Zoetis is available for download. This model provides forecasts for the company's performance from FY2026 through FY2030.
What are Zoetis's capital expenditure plans and assumptions?+
Zoetis's financial model assumes capital expenditure as approximately 7.2% of revenue, historically ranging from 5% to 7%. A significant portion, about 60%, is allocated to growth capex, specifically for expanding biological manufacturing capacity in the U.S. and Ireland to support key product rollouts.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Pharmaceuticals Company Financial Models
Browse another company in the same sector.
AbbVie
AbbVie is a global, research-based biopharmaceutical company that discovers and delivers innovative medicines and aesthetic products.
Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics, focusing on areas of high unmet medical need.
Biogen
Biogen is a global biotechnology company that discovers, develops, and delivers therapies for neurological, immunological, and rare diseases, including multiple sclerosis and Alzheimer's treatments.
Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercialises innovative medicines in areas of unmet medical need.
Incyte
Incyte Corporation is a global commercial-stage biopharmaceutical company focused on the discovery, development, and commercialisation of proprietary therapeutics, primarily in haematology, oncology, and inflammation and autoimmunity (IAI).
Johnson & Johnson
Johnson & Johnson is a diversified global healthcare leader engaged in the research, development, manufacture, and sale of pharmaceutical products and medical devices.
Lilly (Eli)
Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and markets human medicines, with a dominant focus on cardiometabolic diseases, oncology, immunology, and neuroscience.
Explore more Healthcare financial model templates.
